The multivalent toxoid vaccine made by LimmaTech Biologics, a Switzerland-based drug company, is designed to prevent skin and soft tissue infections caused by the bacterial pathogen. There are currently no FDA-approved vaccines for Staph aureus infections, according to a Dec. 19 news release.
By gaining the agency’s fast-track authorization, LimmaTech can discuss the clinical development plan for the vaccine, LBT-SA7, with the FDA more frequently than normal.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
